| 31st Mar 2021 7:00 am |
GNW |
Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®) |
| 30th Mar 2021 7:00 am |
GNW |
Amryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS |
| 29th Mar 2021 7:00 am |
GNW |
Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®) |
| 23rd Mar 2021 7:00 am |
GNW |
Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy |
| 22nd Mar 2021 7:00 am |
GNW |
Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin) |
| 15th Mar 2021 10:00 am |
GNW |
Director/PDMR Shareholding |
| 12th Mar 2021 7:00 am |
GNW |
Exercise of Options and Total Voting Rights |
| 11th Mar 2021 11:30 am |
GNW |
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights |
| 8th Mar 2021 6:00 pm |
GNW |
Director/PDMR Shareholding |
| 8th Mar 2021 7:00 am |
GNW |
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada |
| 4th Mar 2021 12:00 pm |
RNS |
Amryt Announces Record FY 2020 Results |
| 25th Feb 2021 7:00 am |
RNS |
Amryt Supports Global Rare Disease Day 2021 |
| 24th Feb 2021 7:00 am |
GNW |
Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021 |
| 10th Feb 2021 7:00 am |
RNS |
Amryt to Present at SVB Leerink Conference |
| 4th Feb 2021 7:00 am |
GNW |
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel |
| 20th Jan 2021 7:00 am |
GNW |
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales |
| 6th Jan 2021 7:00 am |
RNS |
Amryt to present at H.C Wainwright Conference |
| 23rd Dec 2020 7:00 am |
GNW |
Amryt Granted Orphan Drug Designation by the FDA for AP103 |
| 17th Dec 2020 7:00 am |
GNW |
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia |
| 11th Dec 2020 10:00 am |
GNW |
Holding(s) in Company |
| 9th Dec 2020 2:45 pm |
GNW |
Holding(s) in Company |
| 9th Dec 2020 7:00 am |
GNW |
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil |
| 8th Dec 2020 7:00 am |
GNW |
Amryt Announces $40m Private Placement with Leading Biotech Investors |
| 5th Nov 2020 12:00 pm |
GNW |
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance |
| 29th Oct 2020 7:00 am |
GNW |
AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA |
| 19th Oct 2020 7:00 am |
GNW |
Amryt and Swixx Sign Distribution Deal for Lojuxta |
| 14th Oct 2020 7:00 am |
RNS |
AMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020 |
| 14th Oct 2020 7:00 am |
GNW |
Notice of Results |
| 12th Oct 2020 11:00 am |
GNW |
Holding(s) in Company |
| 9th Oct 2020 7:00 am |
GNW |
Virtual Analyst & Investor Event - Tuesday November 3, 2020 |
| 8th Oct 2020 7:00 am |
GNW |
AMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020 |
| 1st Oct 2020 7:00 am |
GNW |
Exercise of Options and Total Voting Rights |
| 30th Sep 2020 12:30 pm |
GNW |
Holding(s) in Company |
| 23rd Sep 2020 7:00 am |
RNS |
AMRYT SUPPORTS GLOBAL FH AWARENESS DAY |
| 21st Sep 2020 11:00 am |
GNW |
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights |
| 15th Sep 2020 7:00 am |
RNS |
POSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION |
| 9th Sep 2020 2:05 pm |
RNS |
Second Price Monitoring Extn |
| 9th Sep 2020 2:00 pm |
RNS |
Price Monitoring Extension |
| 9th Sep 2020 7:00 am |
RNS |
POSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB |
| 11th Aug 2020 11:09 am |
RNS |
CANCELLATION OF ADMISSION TO EURONEXT GROWTH |
